Sidoti Csr Issues Positive Outlook for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Sidoti Csr upped their Q3 2025 EPS estimates for shares of USANA Health Sciences in a research note issued on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will earn $0.72 per share for the quarter, up from their prior estimate of $0.70. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2025 earnings at $0.72 EPS, Q3 2026 earnings at $0.98 EPS and Q3 2026 earnings at $0.98 EPS.

A number of other analysts have also issued reports on USNA. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Finally, DA Davidson dropped their price objective on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday.

USANA Health Sciences Price Performance

NYSE USNA opened at $29.55 on Friday. The company has a 50 day simple moving average of $33.50 and a 200-day simple moving average of $36.56. The firm has a market capitalization of $563.22 million, a price-to-earnings ratio of 10.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 52-week low of $27.71 and a 52-week high of $50.32.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently added to or reduced their stakes in the company. Martingale Asset Management L P increased its holdings in USANA Health Sciences by 2.1% in the third quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock worth $634,000 after buying an additional 340 shares during the last quarter. KBC Group NV increased its holdings in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after buying an additional 519 shares during the last quarter. R Squared Ltd acquired a new position in USANA Health Sciences in the fourth quarter worth approximately $28,000. Safe Harbor Fiduciary LLC acquired a new position in USANA Health Sciences in the third quarter worth approximately $30,000. Finally, Exchange Traded Concepts LLC increased its holdings in USANA Health Sciences by 11.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock worth $308,000 after buying an additional 869 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.